Loading…
Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma
Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicat...
Saved in:
Published in: | Scientific reports 2024-01, Vol.14 (1), p.624-624, Article 624 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23 |
---|---|
cites | cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23 |
container_end_page | 624 |
container_issue | 1 |
container_start_page | 624 |
container_title | Scientific reports |
container_volume | 14 |
creator | Wang, Ning Hu, Yifeng Wang, Shasha Xu, Qin Jiao, Xiaojing Wang, Yanliang Yan, Lei Cao, Huixia Shao, Fengmin |
description | Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lnc |
doi_str_mv | 10.1038/s41598-024-51197-2 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4</doaj_id><sourcerecordid>2911840731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</originalsourceid><addsrcrecordid>eNp9kcuOFSEQhjtG40zGeQEXhsSNm1au3bCcjLdJJpoYXRMaihNOaDhCt8k8ha8s5_Q4GheygErVxw9Vf9c9J_g1wUy-qZwIJXtMeS8IUWNPH3XnFHPRU0bp47_is-6y1j1uS1DFiXranTFJJB04Pe9-voUfEPNhhrSg7JFBKbcEcqGu0Qd3WHINtS8QzQIOxWS_fLpCNeySWdYCyOeCDiXvUq5LsMgkh8I8rwlQgXrIqUIrgwt2CTmhkJCNYAqyEGMjkolbaE2xIeXZPOueeBMrXN6fF9239---Xn_sbz9_uLm-uu0tl2LpPR0kM8AIMDcJSynnwjPLJk7VpHCbjAJFrBgFYw6PMBk5qcFgR_2E284uuptN12Wz14cSZlPudDZBnxK57LQpraMI2nMrBuoN4FFxyqQyeLLY-YEbLAF403q1abVBfF-hLnoO9diWSZDXqqkiRHI8MtLQl_-g-7yWNoYT1RAu1ZGiG2VLrrWAf_ggwfrovt7c1819fXJfHzt6cS-9TjO4hyu_vW4A24DaSmkH5c_b_5H9Ba7Yu7s</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2910734891</pqid></control><display><type>article</type><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><source>Publicly Available Content Database</source><source>PubMed</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</creator><creatorcontrib>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</creatorcontrib><description>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-024-51197-2</identifier><identifier>PMID: 38182642</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/114/2397 ; 631/67/1857 ; 692/4025/2768/1588/1351 ; 692/4028/67/589/1588/1351 ; Cancer therapies ; Cell death ; Clear cell-type renal cell carcinoma ; Correlation analysis ; Decision making ; Genomes ; Humanities and Social Sciences ; Immune response ; Immunotherapy ; Infiltration ; Kidney cancer ; Medical prognosis ; Metastases ; multidisciplinary ; Non-coding RNA ; Patients ; Prognosis ; Regression analysis ; Risk groups ; Science ; Science (multidisciplinary) ; Tumors</subject><ispartof>Scientific reports, 2024-01, Vol.14 (1), p.624-624, Article 624</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</citedby><cites>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2910734891/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2910734891?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38182642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Hu, Yifeng</creatorcontrib><creatorcontrib>Wang, Shasha</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Jiao, Xiaojing</creatorcontrib><creatorcontrib>Wang, Yanliang</creatorcontrib><creatorcontrib>Yan, Lei</creatorcontrib><creatorcontrib>Cao, Huixia</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</description><subject>631/114/2397</subject><subject>631/67/1857</subject><subject>692/4025/2768/1588/1351</subject><subject>692/4028/67/589/1588/1351</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Correlation analysis</subject><subject>Decision making</subject><subject>Genomes</subject><subject>Humanities and Social Sciences</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Infiltration</subject><subject>Kidney cancer</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>multidisciplinary</subject><subject>Non-coding RNA</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Risk groups</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tumors</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kcuOFSEQhjtG40zGeQEXhsSNm1au3bCcjLdJJpoYXRMaihNOaDhCt8k8ha8s5_Q4GheygErVxw9Vf9c9J_g1wUy-qZwIJXtMeS8IUWNPH3XnFHPRU0bp47_is-6y1j1uS1DFiXranTFJJB04Pe9-voUfEPNhhrSg7JFBKbcEcqGu0Qd3WHINtS8QzQIOxWS_fLpCNeySWdYCyOeCDiXvUq5LsMgkh8I8rwlQgXrIqUIrgwt2CTmhkJCNYAqyEGMjkolbaE2xIeXZPOueeBMrXN6fF9239---Xn_sbz9_uLm-uu0tl2LpPR0kM8AIMDcJSynnwjPLJk7VpHCbjAJFrBgFYw6PMBk5qcFgR_2E284uuptN12Wz14cSZlPudDZBnxK57LQpraMI2nMrBuoN4FFxyqQyeLLY-YEbLAF403q1abVBfF-hLnoO9diWSZDXqqkiRHI8MtLQl_-g-7yWNoYT1RAu1ZGiG2VLrrWAf_ggwfrovt7c1819fXJfHzt6cS-9TjO4hyu_vW4A24DaSmkH5c_b_5H9Ba7Yu7s</recordid><startdate>20240105</startdate><enddate>20240105</enddate><creator>Wang, Ning</creator><creator>Hu, Yifeng</creator><creator>Wang, Shasha</creator><creator>Xu, Qin</creator><creator>Jiao, Xiaojing</creator><creator>Wang, Yanliang</creator><creator>Yan, Lei</creator><creator>Cao, Huixia</creator><creator>Shao, Fengmin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20240105</creationdate><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><author>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/114/2397</topic><topic>631/67/1857</topic><topic>692/4025/2768/1588/1351</topic><topic>692/4028/67/589/1588/1351</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Correlation analysis</topic><topic>Decision making</topic><topic>Genomes</topic><topic>Humanities and Social Sciences</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Infiltration</topic><topic>Kidney cancer</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>multidisciplinary</topic><topic>Non-coding RNA</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Risk groups</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Hu, Yifeng</creatorcontrib><creatorcontrib>Wang, Shasha</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Jiao, Xiaojing</creatorcontrib><creatorcontrib>Wang, Yanliang</creatorcontrib><creatorcontrib>Yan, Lei</creatorcontrib><creatorcontrib>Cao, Huixia</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ning</au><au>Hu, Yifeng</au><au>Wang, Shasha</au><au>Xu, Qin</au><au>Jiao, Xiaojing</au><au>Wang, Yanliang</au><au>Yan, Lei</au><au>Cao, Huixia</au><au>Shao, Fengmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2024-01-05</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>624</spage><epage>624</epage><pages>624-624</pages><artnum>624</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38182642</pmid><doi>10.1038/s41598-024-51197-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2024-01, Vol.14 (1), p.624-624, Article 624 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4 |
source | Publicly Available Content Database; PubMed; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access |
subjects | 631/114/2397 631/67/1857 692/4025/2768/1588/1351 692/4028/67/589/1588/1351 Cancer therapies Cell death Clear cell-type renal cell carcinoma Correlation analysis Decision making Genomes Humanities and Social Sciences Immune response Immunotherapy Infiltration Kidney cancer Medical prognosis Metastases multidisciplinary Non-coding RNA Patients Prognosis Regression analysis Risk groups Science Science (multidisciplinary) Tumors |
title | Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20novel%20disulfidptosis-related%20lncRNA%20signature%20for%20prognostic%20and%20immune%20response%20prediction%20in%20clear%20cell%20renal%20cell%20carcinoma&rft.jtitle=Scientific%20reports&rft.au=Wang,%20Ning&rft.date=2024-01-05&rft.volume=14&rft.issue=1&rft.spage=624&rft.epage=624&rft.pages=624-624&rft.artnum=624&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-024-51197-2&rft_dat=%3Cproquest_doaj_%3E2911840731%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2910734891&rft_id=info:pmid/38182642&rfr_iscdi=true |